||1R01CA266402-01 Interpret this number
||Ohio State University
||Improving Treatment Selection in Advanced Ovarian Cancer
The goal of this proposal is to improve treatment selection and survival in women with advanced ovarian
cancer. Ovarian cancer is the leading cause of deaths from gynecologic cancers in the U.S. Most women
present with advanced disease, with distant spread at the time of diagnosis. Even so, more than 1 in 10 of
such women will survive >10 years after an initial diagnosis, usually with periodic recurrences. The possibility
of long-term survival underscores the paramount importance of each treatment decision.
Determining the best treatment strategy for an individual patient is difficult. For women with newly diagnosed,
advanced ovarian cancer, both surgery and chemotherapy are recommended. However, many women fail to
complete both, rates of death from surgery are high, and chemotherapy delivery is often limited by toxicities.
New therapies that are designed to target cells at the molecular level (“PARP inhibitors”) have recently been
approved for use, but their benefits vary based on the presence of specific tumor mutations, and their costs
exceed $150,000/year. Carefully tailored decisions about the sequence of surgery and chemotherapy, types of
chemotherapy, and the way chemotherapy is delivered, could improve long-term outcomes and reduce costs.
To address this problem, we will build a simulation modeling framework that projects the outcomes of women
treated for advanced ovarian cancer, and use it to identify personalized treatment approaches. We have built a
preliminary model that projects outcomes for women with newly diagnosed, advanced ovarian cancer. We will
extend our model to include detailed patient and tumor characteristics – age, comorbidities, stage, and
mutation status – that influence survival, as well as new therapies and toxicities (Aim 1.1). We will also
simulate the treatment of recurrent cancer (Aim 1.2). Using our new modeling framework, we will identify
tailored treatment approaches that optimize survival (Aim 2.1), minimize treatment toxicities (Aim 2.2), and are
cost-effective (Aim 3). Finally, we will identify future studies that are likely to have the greatest impact in
improving treatment decisions (Aim 4).
To ensure that our findings are accessible to patients, physicians, and policymakers, we will create an online,
interactive version of our modeling framework that can project outcomes, quantify trade-offs, and support
decision-making in real time. The proposed research will result in: 1) personalized treatment
recommendations; 2) real-time guidance for decision-making; 3) the capacity to rapidly weigh benefits of new
therapies with long-term risks and costs; and 4) prioritization of future research. The knowledge gained will
provide new opportunities to improve treatment selection and survival in ovarian cancer.
If you are accessing this page during weekend or evening hours, the database may currently be offline for maintenance and should operational within a few hours. Otherwise, we have been notified of this error and will be addressing it immediately.
Please contact us
if this error persists.
We apologize for the inconvenience.
- The DCCPS Team.